November 13, 2024
Opna Bio Announces 2024 ASH Presentation Highlighting Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in Multiple Myeloma
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two abstracts have been accepted for poster presentations at the American Society of Hematology (ASH) annual meeting, taking place Dec 7-10, 2024 in San Diego. The presentations will highlight data from Opna’s lead clinical programs, OPN-2853 and OPN-6602.
Read more...November 8, 2024
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
Nammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC) and Nammisome platforms, announces dosing of the first patient in the first in human Phase 1 trial (NCT06582017).
Read more...August 26, 2024
Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor
Opna Bio announced that it has dosed the first patient with OPN-6602, a potent and selective EP300/CBP bromodomain inhibitor, in a Phase 1 clinical study in multiple myeloma. The first patient was dosed at The START Center for Cancer Research in Grand Rapids, Michigan with Dr. Andrew Sochacki, principal investigator, leading the study team.
Read more...August 6, 2024
Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM
Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment Fund (MIF) in a $30M Series B financing round prior to the planned start of a first-in-human Phase 1 study of their lead program, QXL138AM, in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma.
Read more...July 29, 2024
Myeloma Investment Fund Invests in Envisagenics, A.I.-Driven Biotechnology Company
The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Envisagenics, a biotechnology company at the forefront of RNA splicing technology.
Read more...July 11, 2024
Myeloma Investment Fund Invests in Dynamic Cell Therapies to Help Fuel Novel CAR T-Cell Technologies
Dynamic Cell Therapies (DCT) announces an investment of $1M from the Myeloma Investment Fund (MIF), the venture philanthropy subsidiary of the Multiple Myeloma Research Foundation (MMRF), to accelerate the development of novel CAR T-cell technologies for patients with multiple myeloma. DCT is developing technology platforms that will allow CAR T-cells to attack unique and differentiated tumor targets that will allow for durable responses to treatment, and DCT’s propriety CAR T-cells have demonstrated superiority to FDA-approved CAR T-cells in animal models.
Read more...January 26, 2024
In Search of Funds and Finance: Best Practices From Women Life Sciences Leaders
During the week of the 2024 J.P. Morgan Healthcare Conference in San Francisco, our life sciences partners Suzanne Filippi and Laurie Burlingame sat down with women leaders in the industry to talk about how best to secure funding, what developments in the industry they feel are important to watch, and advice for women in the space seeking advancement of their careers and/or companies.
Read more...November 15, 2023
Myeloma Investment Fund Invests in Reverb Therapeutics to Support Debut of its Amplifier™ Platform for Redirecting Endogenous Cytokines
The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Reverb Therapeutics to explore the potential of its antibody-based Amplifier™ platform for the treatment of multiple myeloma with endogenous cytokines that naturally occur within the body.
Read more...October 5, 2023
The Multiple Myeloma Research Foundation (MMRF) Names Stephanie Oestreich, Ph.D., MPA, as Managing Director of the Myeloma Investment Fund (MIF)
The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF). In this role, Dr. Oestreich will lead the overall execution of the MIF’s investment strategy and serve as a member of the MMRF executive leadership team.
“We are thrilled to have Dr. Oestreich join our team as Managing Director of the MIF,” said Michael Andreini, President and CEO, the MMRF. “The MIF invests in the most promising companies that are developing innovative clinical assets and technologies that could be transformative for myeloma patients. Dr. Oestreich brings a wealth of business development experience in biopharma and biotech that will play an invaluable role in the continued growth and impact of our fund.”
Read more...May 31, 2023
KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
Myeloma Investment Fund portfolio company KAHR, a clinical-stage biotech company developing DSP107, a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive immunity to treat solid tumors and blood cancers, today announced positive results from the dose escalation Phase I study of DSP107 in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. The results will be presented as a poster in the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held June 2-6, in Chicago, IL.
Read more...May 25, 2023
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-Mica/B Antibody, at ASCO 2023
Cullinan Oncology, Inc. today announced the first monotherapy clinical data from its Phase 1 study of CLN-619 in patients with advanced solid tumors. Findings from the clinical trial will be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting as a poster presentation during the “Developmental Therapeutics—Immunotherapy” session (poster # 2532) on June 3, 2023, from 8:00 AM-11:00 AM Central Time. CLN-619 is being studied in an ongoing Phase 1 clinical trial both as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
Read more...May 17, 2023
Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer
Myeloma Investment Fund portfolio company Indapta Therapeutics has announced an agreement with the U.S. Food and Drug Administration (FDA) on an Investigational New Drug (IND) application to commence its first-in-human phase 1 trial in patients with multiple myeloma and lymphoma. The study is anticipated to begin in the second half of 2023. It will explore three different dose levels of Indapta’s G-NK cells alone and in combination with interleukin-2 and the monoclonal antibodies, rituximab and daratumuma
Read more...May 16, 2023
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
Nectin Therapeutics, a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088, Nectin’s first-in-class lead immunotherapy drug candidate, for the treatment of multiple myeloma.
Read more...March 17, 2022
MIF Invests in Triumvira Immunologics to Advance Novel (TAC)-T Cell Therapy for the Treatment of Multiple Myeloma
The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced an investment in Triumvira Immunologics (“Triumvira”), an Austin, TX-based clinical-stage biotech developing novel, targeted autologous and allogeneic T cell immunotherapies that co-opt the natural biology of T cells to treat solid tumors and blood cancers.
Read more...February 10, 2022
Myeloma Investment Fund Portfolio Company Indapta Therapeutics, Inc., Announces $50 million in Series A-1 Financing
The Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced its portfolio company Indapta Therapeutics, Inc., has raised more than $50 million in Series A-1 financing and made new appointments to its executive leadership. Indapta is a San Francisco, CA-based biotechnology company focused on developing and commercializing a proprietary NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.
Read more...